1.Double-catheter-balloon technique for embolization of high-flow carotid cavernous fistulas.
Aimin ZHENG ; Zhigang WANG ; Benzhi LIU
Journal of Interventional Radiology 1992;0(01):-
Objective To study the possibility and value of double-catheter-balloon technique for embolization of high-flow carotid cavernous fistula (CCF).Methods Three high-flow CCFs, which can't be completely occluded by 1 detachable balloon, were treated with the technique. By the way of bilateral femoral arteries approach, 2 detachable balloons were advanced to the internal carotid artery (ICA). After passing through the fistula, both balloons were inflated on the venous side in order to occlude the fistula. Results All CCFs were occluded completely and the ICAs remained patent. This procedure was easy and safe without increasing the risk of interventional therapy.Conclusions The application of double-catheter-balloon technique for high-flow CCF should be an effective method of choice during failure of 1 balloon procedure and simultaneously maintainning the patency of ICAs completely.
2.Clinical comprehensive evaluation of recombinant Mycobacterium tuberculosis fusion protein
Xiaofeng NI ; Sha DIAO ; Siyi HE ; Xuefeng JIAO ; Xiao CHENG ; Zhe CHEN ; Zheng LIU ; Linan ZENG ; Deying KANG ; Bin WU ; Chaomin WAN ; Binwu YING ; Hui ZHANG ; Rongsheng ZHAO ; Liyan MIAO ; Zhuo WANG ; Xiaoyu LI ; Maobai LIU ; Benzhi CAI ; Feng QIU ; Feng SUN ; Naihui CHU ; Minggui LIN ; Wei SHA ; Lingli ZHANG
China Pharmacy 2023;34(4):391-396
OBJECTIVE To evaluate the effectiveness, safety, economy, innovation, suitability and accessibility of recombinant Mycobacterium tuberculosis fusion protein (EC), and to provide evidence for selecting skin detection methods for tuberculosis infection diagnosis and auxiliary diagnosis of tuberculosis. METHODS The effectiveness and safety of EC compared with purified protein derivative of tuberculin (TB-PPD) were analyzed by the method of systematic review. Cost minimization analysis, cost-effectiveness analysis and cost-utility analysis were used to evaluate the short-term economy of EC compared with TB-PPD, and cost-utility analysis was used to evaluate the long-term economy. The evaluation dimensions of innovation, suitability and accessibility were determined by systematic review and improved Delphi expert consultation, and the comprehensive score of EC and TB-PPD in each dimension were calculated by the weight of each indicator. RESULTS The scores of effectiveness, safety, economy, innovation and suitability of EC were all higher than those of TB-PPD. The affordability scores of the two drugs were consistent, while the availability score of EC was lower than those of TB-PPD. After considering dimensions and index weight, the scores of effectiveness, safety, economy, innovation, suitability, accessibility and the comprehensive score of EC were all higher than those of TB-PPD. CONCLUSIONS Compared with TB-PPD, EC performs better in all dimensions of effectiveness, safety, economy, innovation, suitability and accessibility. However, it is worth noting that EC should further improve its availability in the dimension of accessibility.